About Me

Jessica Scarborough is a PhD Candidate (G2) in the combined MD/PhD Medical Scientist Training Program (MSTP) at Case Western Reserve University (CWRU). She works with an incredible team, the Theory Division Laboratory, at Cleveland Clinic’s Lerner Research Institute, which is lead by Dr. Jacob Scott. There, her research interests include the extraction of biomarkers to predict therapeutic response in cancer and the evolutionary mechanisms underlying collateral sensitivity and resistance in cancer treatment. She is passionate about translational science improving the lives of patients and is pursuing a Translational Fellowship at CWRU to gain insight into the entrepreneurial skills required to move technologies from bench to bedside.

Download her biosketch or CV.

Interests
  • Evolutionary dynamics of collateral treatment response
  • Cancer therapeutic response prediction
  • Translational entrepreneurship
Education
  • PhD in Systems Biology and Bioinformatics, G2

    Case Western Reserve University

  • MD, Current G2 in MSTP

    Case Western Reserve University

  • MSc in Health Informatics, 2017

    University of San Francisco

  • BSc in Biology, 2016

    University of San Francisco

Software Used Daily

R
python
Python
jupyter
Jupyter Notebook

Experience

 
 
 
 
 
Translational Fellow
Jul 2020 – Jun 2021 Cleveland, OH
Training in entrepreneurship and translation of innovation into commercial ventures via seminars, workshops, and networking in the field of commercial biomedical science.
 
 
 
 
 
Full Time Graduate Student
Case Western Reserve University
May 2019 – Present Cleveland, OH
Works full time in the Theory Division (Scott) Laboratory. Passed qualifying exams to become a PhD candidate in March 2020.
 
 
 
 
 
Medical Student
Case Western Reserve University
Jun 2017 – May 2019 Cleveland, OH
Completed the first two years of didactic training in medical school, while working part time in the Theory Division (Scott) Laboratory. Passed Step 1 of the USMLE exams. Medical school to be completed after PhD defense.
 
 
 
 
 
Content Strategist & Editor
Keas, Inc.
Oct 2014 – May 2017 San Francisco, California
Researched, wrote, and edited health and wellness content for an employee engagement and benefits management platform. Keas was acquired by Welltok in 2016.

Recent Honors and Awards

Please see my CV for full list.

Recent Publications

Quickly discover relevant content by filtering publications.
(2021). Personalizing radiotherapy prescription dose using genomic markers of radiosensitivity and normal tissue toxicity in NSCLC. Journal of Thoracic Oncology.

Cite

(2021). Revisiting a null hypothesis: exploring the parameters of oligometastasis treatment. International Journal of Radiation Oncology Biology* Physics*.

Cite

(2020). A Multi-Outcome Meta-Analysis Method Reveals the Genomic Adjusted Radiation Dose is a Continuous Predictive Biomarker of Radiation Outcome. International Journal of Radiation Oncology, Biology, Physics.

Cite

(2020). Exploiting convergent evolution to derive a cisplatin sensitivity gene expression signature in epithelial based cancer. American Association for Cancer Research.

Cite

(2020). GARD is a pan-cancer predictor of clinical outcome in radiation treated patients.. medRxiv.

Cite

Contact